YPEL5 Antibody

What is YPEL5 and why is it significant for research?

YPEL5 (yippee-like 5) is a 121 amino acid protein with a molecular weight of approximately 13.8 kDa that belongs to the Yippee protein family. It is significant in research due to its involvement in the CTLH E3 ubiquitin-protein ligase complex that mediates ubiquitination and subsequent proteasomal degradation of the transcription factor HBP1. YPEL5 is widely expressed across multiple tissue types and appears to play important roles in cell division-related functions and development. Recent research has revealed its importance in liver development and functioning, as well as potential roles in regulating interferon production and epigenetic regulation in cancer .

What subcellular localizations does YPEL5 exhibit during the cell cycle?

YPEL5 displays dynamic subcellular localization patterns throughout the cell cycle. During interphase, YPEL5 is primarily localized to the nucleus and centrosome. As the cell progresses through mitosis, YPEL5 changes its location sequentially to the spindle poles, mitotic spindle, and spindle midzone. Finally, during cytokinesis, it is transferred to the midbody. This changing localization pattern suggests that YPEL5 may play multiple roles during different stages of cell division .

What are the common applications for YPEL5 antibodies in research?

YPEL5 antibodies are commonly utilized in several key research applications:

• Western Blot (WB): Used to detect and quantify YPEL5 protein in tissue or cell lysates, typically at dilutions of 1:1000-1:4000

• Immunohistochemistry (IHC): Used to visualize YPEL5 distribution in tissue sections at dilutions of 1:50-1:500

• Immunofluorescence (IF)/Immunocytochemistry (ICC): Used to examine subcellular localization of YPEL5

• ELISA: Used for quantitative detection of YPEL5 in solution

These applications enable researchers to study YPEL5 expression patterns, protein interactions, and functional roles in various biological contexts .

What tissue samples are optimal for YPEL5 antibody validation?

Based on published research and commercial antibody validation data, the following tissues have shown consistent and reliable YPEL5 detection:

When validating a new YPEL5 antibody, researchers should consider using mouse or rat brain tissue for initial western blot characterization, as these consistently show detectable expression levels .

What controls should be included when using YPEL5 antibodies in experimental procedures?

To ensure reliable and reproducible results when working with YPEL5 antibodies, researchers should include the following controls:

• Positive tissue controls: Mouse brain, mouse testis, or rat brain tissues known to express YPEL5

• Negative controls: Primary antibody omission or isotype controls to assess non-specific binding

• Knockdown/knockout validation: YPEL5-depleted samples (via CRISPR, siRNA, or morpholino) to confirm antibody specificity

• Peptide competition assay: Pre-incubating the antibody with its specific immunogen peptide to verify binding specificity

• Molecular weight verification: Confirmation that the detected band appears at the expected size (approximately 14 kDa for YPEL5)

The zebrafish CRISPR mutant model described in the literature provides an excellent example of using genetic knockouts to validate antibody specificity, as western blot analysis with YPEL5 antibody confirmed the loss of Ypel5 protein in homozygous mutants .

How should YPEL5 antibodies be stored and handled to maintain optimal activity?

For optimal maintenance of YPEL5 antibody activity:

• Storage temperature: Store at -20°C for long-term stability (up to one year)

• Short-term storage: Can be kept at 4°C for up to three months

• Avoid freeze-thaw cycles: Repeated freezing and thawing can degrade antibody quality

• Aliquoting: For antibodies in larger volumes, create small aliquots upon receipt to minimize freeze-thaw cycles

• Buffer conditions: Most YPEL5 antibodies are provided in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

• Working dilutions: Prepare fresh working dilutions on the day of experiment

• Temperature exposure: Do not expose antibodies to prolonged high temperatures

These storage and handling practices are consistent across multiple commercial suppliers and are critical for maintaining antibody functionality and experimental reproducibility .

How can researchers effectively use YPEL5 antibodies to study its role in cell division?

To investigate YPEL5's role in cell division using antibodies:

• Co-localization studies: Combine YPEL5 antibodies with markers for centrosomes (γ-tubulin), mitotic spindles (α-tubulin), or midbody (Aurora B) in ICC/IF experiments to track its dynamic localization during mitosis.

• Cell cycle synchronization: Use techniques like double thymidine block or nocodazole treatment to synchronize cells at specific cell cycle stages, then use YPEL5 antibodies to quantify expression or localization changes.

• Live cell imaging: Consider generating GFP-tagged YPEL5 constructs and validate expression patterns with antibodies before conducting live imaging experiments.

• Proximity ligation assays: Use YPEL5 antibodies in conjunction with antibodies against potential binding partners in the CTLH complex to visualize protein-protein interactions during different cell cycle stages.

• Phosphorylation state analysis: Combine general YPEL5 antibodies with phospho-specific antibodies (if available) to determine how phosphorylation might regulate YPEL5's function during mitosis.

The dynamic subcellular relocalization of YPEL5 during cell division suggests it may function in multiple aspects of mitotic progression, making it an interesting target for cell cycle research .

What methodological approaches can resolve contradictory YPEL5 protein size observations?

While the calculated molecular weight of YPEL5 is approximately 14 kDa (121 amino acids), some research reports have observed higher molecular weights in western blot analyses (up to 68 kDa in some cases). To resolve these contradictions:

• Denaturing conditions: Use strong denaturing conditions (8M urea or 6M guanidine HCl) to disrupt potential protein complexes that may resist standard SDS-PAGE separation.

• Cross-validation with multiple antibodies: Test several antibodies targeting different epitopes of YPEL5 to confirm consistent molecular weight detection.

• Mass spectrometry validation: Excise bands from gels for protein identification by mass spectrometry to confirm YPEL5 identity.

• Expression systems: Compare recombinant YPEL5 with endogenous protein to identify potential post-translational modifications.

• 2D gel electrophoresis: Use 2D electrophoresis to separate proteins by both isoelectric point and molecular weight to identify potential isoforms or modifications.

• Western blot optimization: Adjust reducing agent concentration, sample preparation method, and gel percentage to ensure complete protein denaturation and optimal separation.

These methodological approaches can help clarify whether the observed size differences represent true biological phenomena (post-translational modifications, alternatively spliced variants) or technical artifacts .

How can YPEL5 antibodies be employed to study its role in liver development based on recent findings?

Based on zebrafish studies showing YPEL5's role in liver development, researchers can employ the following methodological approaches:

• Developmental time-course studies: Use YPEL5 antibodies in IHC or IF to track expression patterns during key stages of liver development across model organisms.

• Co-staining with liver markers: Combine YPEL5 antibodies with hepatocyte markers (HNF4A, FABP10A) to assess cellular specificity and potential regulatory relationships.

• Proliferation analysis: Co-stain with proliferation markers (Ki-67, PCNA, BrdU) to evaluate YPEL5's relationship with hepatocyte proliferation, as YPEL5 deficiency leads to hepatocyte hyperproliferation.

• Metabolic pathway analysis: Use YPEL5 antibodies in combination with PPARα and HNF4A antibodies to investigate the molecular pathway through which YPEL5 regulates liver development and function.

• Chromatin immunoprecipitation (ChIP): Use YPEL5 antibodies for ChIP experiments to identify potential DNA binding sites or interactions with chromatin-associated proteins.

• Co-immunoprecipitation (Co-IP): Use YPEL5 antibodies to pull down protein complexes to identify interaction partners in liver tissue or hepatocyte cultures.

This multifaceted approach can help elucidate how YPEL5 regulates liver development through PPARα signaling and HNF4A as demonstrated in the zebrafish model .

What are common issues when using YPEL5 antibodies in Western blotting, and how can they be resolved?

Common issues with YPEL5 antibodies in Western blotting include:

These troubleshooting approaches are based on standard protocols and specific recommendations for YPEL5 antibodies from multiple sources .

How can researchers validate YPEL5 antibody specificity in immunohistochemistry applications?

To validate YPEL5 antibody specificity in immunohistochemistry:

• Antigen retrieval optimization:

  • Test multiple antigen retrieval methods: For YPEL5, both citrate buffer (pH 6.0) and TE buffer (pH 9.0) have been used successfully

  • Compare heat-induced versus enzymatic epitope retrieval methods

• Concentration gradient testing:

  • Establish a dilution series (e.g., 1:50, 1:100, 1:250, 1:500) to determine optimal antibody concentration

  • Evaluate signal-to-noise ratio at each concentration

• Genetic controls:

  • Use YPEL5 knockout/knockdown tissues as negative controls

  • The zebrafish CRISPR model provides an excellent system for validation

• Peptide competition:

  • Pre-incubate antibody with immunizing peptide prior to staining

  • Gradual loss of signal confirms antibody specificity

• Multi-antibody validation:

  • Compare staining patterns using antibodies raised against different YPEL5 epitopes

  • Consistent localization patterns increase confidence in specificity

• Cross-species validation:

  • Test antibody reactivity across species (human, mouse, rat)

  • Conserved proteins like YPEL5 should show similar staining patterns in homologous tissues

• RNA-protein correlation:

  • Compare antibody staining patterns with RNA expression data (in situ hybridization)

  • Concordant patterns support antibody specificity

These validation approaches have been successfully applied to YPEL5 antibodies in published research, particularly in the context of developmental biology studies in zebrafish .

What methodological considerations are important when studying YPEL5's dynamic localization during cell division?

When investigating YPEL5's changing subcellular localization during cell division:

These methodological considerations are essential for accurately characterizing the dynamic behavior of YPEL5 during cell division, consistent with published observations of its changing localization patterns .

How can YPEL5 antibodies be utilized to study its potential role in cancer biology?

Recent research suggests YPEL5 may have roles in cancer biology, with evidence of epigenetic suppression in colorectal cancer. To investigate this connection:

• Expression analysis in cancer tissues:

  • Use YPEL5 antibodies for IHC on tissue microarrays to compare expression between tumor and adjacent normal tissues

  • Quantify differences in expression levels, subcellular localization, and correlation with clinical parameters

• Cell line models:

  • Compare YPEL5 protein levels across cancer cell lines using Western blotting

  • Investigate changes in YPEL5 expression during cancer progression models in vitro

• Functional studies combining genetic manipulation and antibody detection:

  • Overexpress or knockdown YPEL5 in cancer cell lines

  • Use antibodies to confirm manipulation and track downstream effects on cell proliferation, migration, and invasion

• Epigenetic regulation analysis:

  • Combine YPEL5 antibody detection with analysis of m6A methylation machinery components

  • Investigate METTL3/YTHDF2 m6A axis regulation of YPEL5 as reported in colorectal cancer

• Co-immunoprecipitation studies:

  • Use YPEL5 antibodies to identify cancer-specific interaction partners

  • Focus on components of the CTLH E3 ubiquitin-protein ligase complex

• Therapeutic response monitoring:

  • Track changes in YPEL5 expression following treatment with chemotherapeutic agents or targeted therapies

  • Correlate with clinical outcomes to assess potential as biomarker

These approaches leverage YPEL5 antibodies to systematically investigate its role in cancer biology, building on emerging evidence of its potential significance in cancer development and progression .

What methodological approaches can resolve contradictory findings about YPEL5's role in apoptosis versus cell proliferation?

The literature contains seemingly contradictory findings regarding YPEL5's role in cell survival, with some studies suggesting pro-apoptotic functions and others indicating it promotes cell proliferation. To resolve these contradictions:

• Cell type-specific analysis:

  • Use YPEL5 antibodies to compare expression and subcellular localization across diverse cell types

  • Correlate expression patterns with proliferation/apoptosis phenotypes

• Controlled genetic manipulation:

  • Create dose-dependent expression systems (inducible promoters)

  • Monitor effects on apoptosis and proliferation markers using YPEL5 antibodies to confirm expression levels

• Stress condition variation:

  • Examine YPEL5's role under diverse stress conditions (nutrient deprivation, DNA damage, oxidative stress)

  • Use YPEL5 antibodies to track changes in expression and localization in response to different stressors

• Temporal analysis:

  • Conduct time-course experiments following YPEL5 manipulation

  • Use antibodies to monitor both short-term and long-term consequences on cell fate

• Signaling pathway investigation:

  • Combine YPEL5 antibodies with detection of key proliferation and apoptosis pathway components

  • Use pharmacological inhibitors to dissect pathway dependencies

• Post-translational modification analysis:

  • Use phospho-specific antibodies (if available) or general YPEL5 antibodies following phosphatase treatment

  • Determine if phosphorylation states dictate YPEL5's functional outcomes

• Protein interaction network mapping:

  • Use co-immunoprecipitation with YPEL5 antibodies under different cellular conditions

  • Identify condition-specific interaction partners that may explain functional versatility

These methodological approaches can help determine whether YPEL5's apparently contradictory roles represent context-dependent functions, developmental stage-specific effects, or concentration-dependent activities .